Combination of Vaccine Strain Measles Virus and Nimotuzumab in the Treatment of Laryngeal Cancer

• Published in: Anticancer research Vol. 39; no. 7; pp. 3727 - 3737
• Main Authors: Toan, Nguyen Linh, Hang, Ngo Thu, Luu, Nguyen Kim, VAN Mao, Can, VAN Ba, Nguyen, Xuan, Nguyen Thi, Cam, Truong Dinh, Yamamoto, Naoki, VAN Tong, Hoang, Son, Ho Anh
• Format: Journal Article
• Language: English
• Published: Greece International Institute of Anticancer Research 01-07-2019
• Subjects: Animal models; Animals; Antibodies, Monoclonal, Humanized - therapeutic use; Anticancer properties; Antineoplastic Agents - therapeutic use; Cell death; Cell Line, Tumor; Cercopithecus aethiops; Chemoradiotherapy; Combined Modality Therapy; Flow cytometry; Humans; Immunotherapy; Laryngeal cancer; Laryngeal Neoplasms - therapy; Measles; Measles Vaccine; Measles virus; Mice, Nude; Monoclonal antibodies; Oncolysis; Oncolytic Virotherapy; Oncolytic Viruses; Survival; Targeted cancer therapy; Tumors; Vaccines; Vero Cells; Viruses; laryngeal cancer; cancer target; Oncolytic virus; nimotuzumab; monoclonal antibody; Measles virus
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.13521

This study aims to investigate whether the combination of oncolytic viruses with chemoradiotherapy or other therapies is a promising strategy for cancer treatment.
The anticancer effects of measles virus (MeV) in combination with nimotuzumab in the treatment of laryngeal cancer were evaluated in vitro and in nude mice inoculated with Hep2 tumors. MTT assay and flow cytometry were used to examine cell death.
Laryngeal cancer cells treated with MeV+nimotuzumab combination had a significantly lower survival rate compared to those treated with MeV or nimotuzumab alone (p<0.0001). In an animal model bearing human laryngeal tumor, the treated group had a higher survival rate (60%) compared to a untreated group (20%) (p<0.05), and the survival rate of the group treated with MeV+nimotuzumab combination was higher compared to the groups received single treatment.
The MeV+nimotuzumab combination has greater anticancer activities in both laryngeal cancer cells and an animal model.